Today Asia, Tomorrow The World? AstraZeneca Looks To Align R&D Strategy Across Emerging Markets
This article was originally published in PharmAsia News
Executive Summary
WASHINGTON - AstraZeneca PLC is looking to leverage its experience in Asia to catch up with competitors in other fast growing emerging markets like Russia and Brazil, according to Steve Yang, the company's head of R&D in Asia and emerging markets. Yang, who joined AZ in January, is based in Shanghai and reports to R&D President Martin Mackay
You may also be interested in...
AstraZeneca Goes Deeper Into China Cardiovascular Focus With Tianjin Medical University Agreement
AstraZeneca has signed a collaboration agreement with Chinese research institution Tianjin Medical University to co-explore novel targets against cardiac fibrosis. The agreement builds on a string of such academic collaborations in the country focused on growing chronic diseases.
AstraZeneca Forms Research Alliance In China For Chronic Kidney Disease
To bring new treatment for 112 million patients with kidney disease in China, AstraZeneca is establishing a research collaboration with Shenzhen University to discover new medicines for diabetic nephropathy.
AstraZeneca Forms Research Alliance In China For Chronic Kidney Disease
To bring new treatment for 112 million patients with kidney disease in China, AstraZeneca is establishing a research collaboration with Shenzhen University to discover new medicines for diabetic nephropathy.